Abstract
Mpox has emerged as a critical public health challenge, creating an urgent need for rapid, reliable, and field-deployable diagnostic tools for outbreak settings. Here, we present Kairo-CONAN, a novel CRISPR-Cas3-based point-of-care (POC) diagnostic platform for Mpox, engineered for sustainability and portability. This system leverages a disposable hand warmer (Kairo) as a stable heat source and incorporates freeze-dried reagents for ambient temperature stability, enabling device-free, sensitive detection through lateral flow assay strips. Utilizing CRISPR-Cas3’s unique DNA-targeting and cleavage properties, we optimized probe DNA configurations for high specificity and designed clade-specific target crRNAs. Kairo-CONAN demonstrated rapid, high-sensitivity, and specific detection of Mpox virus (MPXV) DNA across multiple clades, including Clade Ia (Congo), Clade Ib (synthetic DNA), and Clade IIb (Tokyo). By addressing logistical and environmental challenges, Kairo-CONAN offers a sustainable, cost-effective, and field-adapted solution for infectious disease diagnostics, aligning with the 100-day mission framework to enhance global outbreak response efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part by JSPS KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) (grant numbers 19KK0401, 22K19238, 22H02266, 23H00367) and a grant from the Japan Agency for Medical Research and Development (AMED) (grant numbers 23ck0106807, 24bm12230009, 223fa627001, JP24jf0126002, JP243fa627001h0003, JP243fa727002, 23fk0108583, JP24fk0108690).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript.
